{"id":"https://openalex.org/W30375896","doi":"https://doi.org/10.1177/030089161209800202","title":"Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors","display_name":"Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors","alternate_titles":[],"publication_year":2012,"publication_date":"2012-03-01","ids":{"openalex":"https://openalex.org/W30375896","doi":"https://doi.org/10.1177/030089161209800202","mag":"30375896","pmid":"https://pubmed.ncbi.nlm.nih.gov/22677983"},"language":"en","primary_location":{"id":"doi:10.1177/030089161209800202","doi":"https://doi.org/10.1177/030089161209800202","is_oa":false,"landing_page_url":"https://doi.org/10.1177/030089161209800202","pdf_url":null,"source":{"id":"https://openalex.org/S4210189328","display_name":"Tumori Journal","issn_l":"0300-8916","issn":["0300-8916","2038-2529"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tumori Journal","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W30375896"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5037582858","display_name":"Ettore Minutilli","orcid":"https://orcid.org/0000-0002-6694-2936","observed_orcids":["https://orcid.org/0000-0002-6694-2936"]},"institutions":[{"id":"https://openalex.org/I103320735","display_name":"Universit\u00e0 Cattolica del Sacro Cuore","ror":"https://ror.org/03h7r5v07","country_code":"IT","type":"education","lineage":["https://openalex.org/I103320735"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Ettore Minutilli","raw_affiliation_strings":["Catholic University of Sacred Heart, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Catholic University of Sacred Heart, Rome, Italy","institution_ids":["https://openalex.org/I103320735"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5017615796","display_name":"Claudio Feliciani","orcid":"https://orcid.org/0000-0003-0883-3210","observed_orcids":["https://orcid.org/0000-0003-0883-3210"]},"institutions":[{"id":"https://openalex.org/I103320735","display_name":"Universit\u00e0 Cattolica del Sacro Cuore","ror":"https://ror.org/03h7r5v07","country_code":"IT","type":"education","lineage":["https://openalex.org/I103320735"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Claudio Feliciani","raw_affiliation_strings":["Catholic University of Sacred Heart, Rome, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Catholic University of Sacred Heart, Rome, Italy","institution_ids":["https://openalex.org/I103320735"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I103320735"],"apc_list":{"value":4150,"currency":"USD","value_usd":4150},"apc_paid":null,"fwci":0.1345,"has_fulltext":false,"cited_by_count":9,"citation_normalized_percentile":{"value":0.12540776,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":93},"biblio":{"volume":"98","issue":"2","first_page":"185","last_page":"190"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.9477999806404114,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.024299999698996544,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.021800000220537186,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adjuvant-therapy","display_name":"adjuvant therapy","score":0.8320000171661377},{"id":"https://openalex.org/keywords/stage-iii-melanoma","display_name":"stage III melanoma","score":0.9010000228881836},{"id":"https://openalex.org/keywords/pegylated-interferon-alpha-2b","display_name":"pegylated interferon alpha-2b","score":0.9639999866485596},{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6710000038146973},{"id":"https://openalex.org/keywords/recurrence-free-survival","display_name":"recurrence-free survival","score":0.7009999752044678},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9959999918937683},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.7919999957084656}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8452545404434204},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8446969985961914},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.69813072681427},{"id":"https://openalex.org/C2909179924","wikidata":"https://www.wikidata.org/wiki/Q6046488","display_name":"Alpha interferon","level":3,"score":0.653498649597168},{"id":"https://openalex.org/C2777982462","wikidata":"https://www.wikidata.org/wiki/Q2481887","display_name":"Adjuvant therapy","level":3,"score":0.6502150297164917},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6156570911407471},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5904824137687683},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.5079918503761292},{"id":"https://openalex.org/C2781228144","wikidata":"https://www.wikidata.org/wiki/Q6046441","display_name":"Interferon alfa","level":4,"score":0.4750245213508606},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.47078317403793335},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.45117396116256714},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.4456920921802521},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4409737288951874},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.39886507391929626},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34042781591415405},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.30388855934143066},{"id":"https://openalex.org/C2776178377","wikidata":"https://www.wikidata.org/wiki/Q188269","display_name":"Interferon","level":2,"score":0.30191171169281006},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2599632143974304},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.25757354497909546},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.23026934266090393}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000077190","descriptor_name":"Interferon alpha-2","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011092","descriptor_name":"Polyethylene Glycols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016898","descriptor_name":"Interferon-alpha","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017410","descriptor_name":"Practice Guidelines as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018572","descriptor_name":"Disease-Free Survival","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1177/030089161209800202","doi":"https://doi.org/10.1177/030089161209800202","is_oa":false,"landing_page_url":"https://doi.org/10.1177/030089161209800202","pdf_url":null,"source":{"id":"https://openalex.org/S4210189328","display_name":"Tumori Journal","issn_l":"0300-8916","issn":["0300-8916","2038-2529"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tumori Journal","raw_type":"journal-article"},{"id":"pmid:22677983","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22677983","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Tumori","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":39,"referenced_works":["https://openalex.org/W1522195858","https://openalex.org/W1828940258","https://openalex.org/W1908752382","https://openalex.org/W1966510725","https://openalex.org/W1967084952","https://openalex.org/W1974406139","https://openalex.org/W1977607846","https://openalex.org/W1979143050","https://openalex.org/W1990435553","https://openalex.org/W1994572966","https://openalex.org/W2031188948","https://openalex.org/W2044013554","https://openalex.org/W2066068067","https://openalex.org/W2095826876","https://openalex.org/W2097995306","https://openalex.org/W2099289479","https://openalex.org/W2100221982","https://openalex.org/W2100429595","https://openalex.org/W2102041421","https://openalex.org/W2106543129","https://openalex.org/W2106981111","https://openalex.org/W2118449798","https://openalex.org/W2118863192","https://openalex.org/W2120918364","https://openalex.org/W2123628301","https://openalex.org/W2126633948","https://openalex.org/W2128542677","https://openalex.org/W2130913838","https://openalex.org/W2136443107","https://openalex.org/W2137634902","https://openalex.org/W2143793874","https://openalex.org/W2155242817","https://openalex.org/W2161204007","https://openalex.org/W2161671887","https://openalex.org/W2164918836","https://openalex.org/W2167925208","https://openalex.org/W2170008127","https://openalex.org/W2240139162","https://openalex.org/W4249425552"],"related_works":["https://openalex.org/W2997351648","https://openalex.org/W2002265007","https://openalex.org/W2125716623","https://openalex.org/W1972512828","https://openalex.org/W2100221982","https://openalex.org/W2583641997","https://openalex.org/W2788701954","https://openalex.org/W2156249402","https://openalex.org/W2343701152","https://openalex.org/W2134825823"],"abstract_inverted_index":{"High-dose":[0],"interferon-alpha":[1,35,95,274],"remains":[2],"the":[3,7,22,65,106,113,143,219,248,255,262],"first-line":[4],"treatment":[5,68,107,220],"in":[6,54,79,123,151,196,214],"adjuvant":[8,30,67,258],"therapy":[9,31,42,187,259],"of":[10,43,81,108,153,177,221],"metastatic":[11,72,110,241],"melanoma.":[12,111],"More":[13],"recently,":[14],"high-dose":[15,34,94,138,167,273],"pegylated":[16,168],"interferon-alpha-2b":[17],"has":[18,51],"been":[19,52,212],"approved":[20],"by":[21,38],"US":[23],"Food":[24],"and":[25,96,118,228,275],"Drug":[26],"Administration.":[27],"Actually,":[28],"an":[29],"alternative":[32],"to":[33,62,190,236,251,260,269],"is":[36,60,69,188],"represented":[37],"ipilimumab.":[39],"Moreover,":[40],"combination":[41,215],"IFN-alpha":[44],"or":[45,99,278],"ipilimumab":[46,97,184,276],"with":[47,56,101,137,166,216,225,254,272,280],"tyrosine":[48,102,208,281],"kinase":[49,103,209,282],"inhibitors":[50,104,210,283],"proved":[53],"patients":[55,133,164,199,224,243],"specific":[57],"mutations.":[58],"It":[59],"mandatory":[61],"understand":[63],"what":[64],"best":[66,263],"for":[70,105,130,160,218,286],"resected":[71],"melanoma":[73,132,163,198,223,242],"patients,":[74],"particularly":[75],"at":[76],"stage":[77,161],"III-N1,":[78],"terms":[80,152],"overall":[82,128,158,193,264],"survival":[83,125,129,155,159,194],"rather":[84,156],"than":[85,127,157],"recurrence-free":[86,124,154],"survival.":[87,265],"The":[88],"ECOG":[89,115,289],"1609":[90],"clinical":[91],"trial":[92,146],"compared":[93],"alone":[98,277],"combined":[100,279],"early":[109],"In":[112],"past,":[114],"1684,":[116],"1690":[117],"1694":[119],"trials":[120,180],"showed":[121],"improvement":[122],"more":[126,141,172,238],"high-risk":[131],"(stage":[134,244],"IIB-III)":[135],"treated":[136,165,253],"interferon-alpha,":[139],"whereas":[140],"recently":[142],"EORTC":[144],"18991":[145],"reported":[147],"successful":[148],"therapeutic":[149],"results":[150,287],"III-N1":[162],"interferon-alpha-2b.":[169],"Toxicity":[170],"was":[171],"acceptable":[173],"within":[174],"one":[175],"year":[176],"treatment.":[178],"Randomized":[179],"have":[181,211,268],"demonstrated":[182],"that":[183],"as":[185],"second-line":[186],"able":[189],"increase":[191],"dose-dependent":[192],"rates":[195],"advanced":[197,222],"despite":[200],"severe":[201],"but":[202,231],"reversible":[203],"immune-related":[204],"adverse":[205],"events.":[206],"Old":[207],"used":[213],"interferon":[217],"moderate":[226],"benefits":[227],"increased":[229],"toxicity,":[230],"new":[232],"selective":[233],"drugs":[234],"seem":[235],"be":[237,247,252,270],"efficacious.":[239],"Early":[240],"III-N1)":[245],"should":[246],"principal":[249],"subset":[250],"most":[256],"suitable":[257],"achieve":[261],"New":[266],"schedules":[267],"tested":[271],"while":[284],"waiting":[285],"from":[288],"1609.":[290]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W30375896","counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-14T11:04:58.165337","created_date":"2016-06-24T00:00:00"}
